The clinical goal for prescribing exercise dictates the regimen. A prescription for managing treatment-related fatigue will differ significantly from one intended as a direct anti-cancer therapy or for preventing long-term cardiometabolic disease. The type, dose, and intensity must match the specific indication.

A common clinical observation is that patients who develop significant immune-related toxicities, like colitis or pneumonitis, are frequently the same ones who experience the most profound and durable responses to checkpoint inhibitor therapy.

A practical, gold-standard clinical test for oncologists to quickly screen for LEMS is to ask a patient to stand from a chair without using their arms. An inability to do so is a strong, immediate indicator of proximal leg weakness—a hallmark of LEMS—and should trigger a more comprehensive workup.

While new systemic treatments for desmoid tumors can effectively control the disease and improve quality of life by managing symptoms, they introduce their own set of side effects. This creates a clinical challenge where the positive impact on the tumor must be carefully weighed against the negative impact of the treatment itself on the patient's daily life.

The mHSPC phase is considered the patient's "best bit of the rest of your life." When considering triplet therapies, clinicians favor options with a fixed, shorter duration of toxicity (like lutetium) over continuous treatments (like capivasertib) to minimize the negative impact on this crucial period of high quality of life.

Chemotherapy is known to worsen metabolic parameters, but this should be viewed as an opportunity, not just a side effect. By actively correcting this metabolic dysfunction with adjunctive therapies, clinicians may be able to enhance the overall life-saving benefit of the chemotherapy itself.

Experts express concern that the paraneoplastic syndrome LEMS is frequently missed in SCLC patients. Its primary symptom, proximal muscle weakness, is often attributed to the cancer itself or treatment side effects, leading clinicians to overlook the specific diagnostic test for this distinct and potentially treatable condition.

Though ADCs like Sacituzumab Govitekan cause notable side effects like diarrhea and neutropenia, patient-reported outcome data shows they provide a meaningful and sustained improvement in quality of life compared to standard chemotherapy. This was observed even with longer treatment durations and lower discontinuation rates.

Patients are often exhausted after primary treatment and surprised by the recommendation for two additional years of intensive oral therapy. Clinicians should introduce this possibility early in the treatment journey to manage expectations and prevent the patient from feeling overwhelmed later on.